A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.
Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy
- Post author:
- Post published:November 5, 2024
- Post category:uncategorized